Palonosetron

• A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post COVID-1… Not authorised
  2023-504087-42-00 Phase III 1 country Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocio…
• A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer Pending
  2025-522204-24-00 Phase II 4 countries Eli Lilly & Co.
• Postoperative recovery with the addition of long-acting NK1- and 5-HT3 receptor antagonists as prophylaxis for post-operative nausea and vom… Pending
  2025-522529-36-00 Phase III 1 country Region Vaesternorrland; Umea University
• Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting
  2024-515698-85-00 Phase III 15 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate… Recruiting
  2024-511309-47-00 Phase II 13 countries Karyopharm Therapeutics Inc.
• Phase II proof-of-concept, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of plitidepsin in adults w… Ended
  2024-516378-31-00 Phase II 1 country Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocio…
• A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation Ended
  2023-503714-77-00 Phase II 6 countries Mirati Therapeutics Inc.
• A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended
  2023-506139-13-00 Phase III 13 countries Karyopharm Therapeutics Inc.

Showing 1–8 of 8 trials